Get the Stockscreener App
4.98
0.40%
-0.02
Moleculin Biotech Inc stock is traded at $4.98, with a volume of 193.18K.
It is down -0.40% in the last 24 hours and down -59.15% over the past month.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
See More
Previous Close:
$5.00
Open:
$5.06
24h Volume:
193.18K
Relative Volume:
1.00
Market Cap:
$10.31M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.3256
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
-31.22%
1M Performance:
-59.15%
6M Performance:
-70.20%
1Y Performance:
-91.90%
1-Day Range:
$4.75
$5.20
1-Week Range:
$4.75
$7.98
52-Week Range:
$4.75
$91.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
4.98 | 10.35M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Resumed | H.C. Wainwright | Buy |
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Moleculin Biotech (MBRX) Sees Significant Price Target Upgrade - GuruFocus
HC Wainwright & Co. Maintains Moleculin Biotech (MBRX) Buy Recommendation - Nasdaq
Moleculin Biotech raises $6.5 million through warrant exercise By Investing.com - Investing.com Nigeria
Moleculin Biotech Enters Inducement Offer Agreements - TipRanks
Moleculin Biotech stock falls after warrant exercise agreement By Investing.com - Investing.com UK
Moleculin Biotech stock falls after warrant exercise agreement - Investing.com India
Moleculin Biotech raises $6.5 million through warrant exercise - Investing.com
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds - The Manila Times
Moleculin Biotech, Inc. Announces Immediate Exercise of Warrants for Gross Proceeds of Approximately $6.5 Million - Quiver Quantitative
Moleculin Biotech (Nasdaq: MBRX) enters warrant exercise deals for approx $6.5M - Stock Titan
Moleculin Biotech (MBRX) Stock: Faces Market Drop Despite Positive MIRACLE Trial Enrollment Progress - parameter.io
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech (MBRX) Approaches Key Enrollment Milestone in Leukemia Study - GuruFocus
Moleculin Biotech Updates on MIRACLE Study Progress - TipRanks
Moleculin stock rises as AML trial enrollment reaches 78% By Investing.com - Investing.com Nigeria
Moleculin Biotech, Inc. Updates on MIRACLE Phase 2B/3 AML Trial Progress - TradingView — Track All Markets
Moleculin stock rises as AML trial enrollment reaches 78% - Investing.com
Moleculin reports 78% enrollment in AML treatment trial - Investing.com
Moleculin reports 78% enrollment in AML treatment trial By Investing.com - Investing.com South Africa
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal 'MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - The Manila Times
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - Sahm
Moleculin Announces Completion of Treatment for the 45 - GlobeNewswire
Moleculin enters research agreement for brain cancer treatment By Investing.com - Investing.com South Africa
Moleculin Biotech Partners with CIC biomaGUNE for Research - TipRanks
Moleculin Biotech (MBRX) Partners with CIC biomaGUNE for Brain C - GuruFocus
Moleculin enters research agreement for brain cancer treatment - Investing.com
Moleculin Announces New Annamycin Collaboration in Brain Tumors - The Manila Times
Moleculin Biotech, Inc. Partners with CIC biomaGUNE for Preclinical Research on Annamycin as a Treatment for Glioblastoma Multiforme - Quiver Quantitative
Moleculin announces new Annamycin collaboration in brain tumors - marketscreener.com
Moleculin (Nasdaq: MBRX) joins CIC biomaGUNE to study Annamycin in GBM models - Stock Titan
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN
Moleculin Biotech (MBRX) Price Target Increased by 2,399.99% to 170.00 - Nasdaq
Net debt of Moleculin Biotech, Inc. – FWB:MOL0 - TradingView
After tax other income/expense of Moleculin Biotech, Inc. – MUN:MOL0 - TradingView
Basic earnings per share (basic EPS) of Moleculin Biotech, Inc. – LS:A41SET - TradingView
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Geopolitics Watch: Why Moleculin Biotech Inc. stock remains a top recommendationJuly 2025 Reactions & Fast Momentum Entry Tips - BỘ NỘI VỤ
Moleculin Biotech, Inc.: Revenue and Earnings Analysts Forecasts Revisions | MOL0 | US60855D4088 - marketscreener.com
Moleculin Biotech, Inc.: Financial Data Forecasts Estimates and Expectations | MOL0 | US60855D4088 - marketscreener.com
Moleculin Biotech, Inc.: Dividend historical data and projections - marketscreener.com
Moleculin Biotech, Inc.: Target Price Consensus and Analysts Recommendations | MOL0 | US60855D4088 - marketscreener.com
How supply shortages influence Moleculin Biotech Inc. (MOL) stockPortfolio Profit Report & Precise Swing Trade Alerts - Newser
Moleculin Biotech Inc (FRA:MOL0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Moleculin Biotech Inc (FRA:MOL0) Stock Earnings Transcripts - GuruFocus
Why Moleculin Biotech Inc. stock attracts global investors2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
Enterprise value to EBITDA ratio of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Price to cash flow ratio of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Why analysts maintain buy rating on Moleculin Biotech Inc. (MOL) stockGDP Growth & Reliable Momentum Entry Alerts - Newser
Number of employees of Moleculin Biotech, Inc. – MUN:MOL0 - TradingView
Moleculin Biotech, Inc. Financial Statements – FWB:MOL0 - TradingView
Net debt of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):